Show simple item record

dc.contributor.authorKolotkin, Ronette L.
dc.contributor.authorFujioka, K.
dc.contributor.authorWolden, M.L.
dc.contributor.authorBrett, J.H.
dc.contributor.authorBjorner, J.B.
dc.date.accessioned2019-04-12T07:25:21Z
dc.date.available2019-04-12T07:25:21Z
dc.date.created2016-05-24T09:24:43Z
dc.date.issued2016
dc.identifier.citationKolotkin, R. L., Fujioka, K., Wolden, M. L., Brett, J. H., & Bjorner, J. B. (2016). Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity, 6(4), 233-242.nb_NO
dc.identifier.issn1758-8111
dc.identifier.urihttp://hdl.handle.net/11250/2594368
dc.description.abstractObesity has a negative impact on health‐related quality of life (HRQoL). The SCALE Obesity and Prediabetes study investigated the effect of liraglutide 3.0 mg, as adjunct to diet and exercise, on HRQoL in patients with obesity [body mass index (BMI) ≥ 30 kg m−2] or overweight (BMI ≥ 27 kg m−2) with comorbidity. Participants were advised on a 500 kcal d−1 deficit diet and a 150‐min week−1 exercise programme and were randomised 2:1 to once‐daily subcutaneous liraglutide 3.0 mg or placebo. HRQoL was assessed using the Impact of Weight on Quality of Life‐Lite (IWQOL‐Lite) and Short‐Form 36 (SF‐36) v2 health questionnaires. Individuals on liraglutide 3.0 mg (n = 2046) had significantly greater improvements in IWQOL‐Lite total score (10.6 ± 13.3) vs. placebo (n = 1020) (7.7 ± 12.8) and SF‐36 physical (PCS) and mental (MCS) component summary scores (PCS, 3.6 ± 6.8; MCS, 0.2 ± 8.1) vs. placebo (PCS, 2.2 ± 7.7; MCS, −0.9 ± 9.1). The estimated treatment differences were IWQOL‐Lite total score 3.1 (95% CI: 2.2; 4.0), P < 0.0001; SF‐36 PCS 1.7 (95% CI: 1.2; 2.2), P < 0.0001 and MCS 0.9 (95% CI: 0.3; 1.5), P = 0.003. All subscales of the IWQOL‐Lite and SF‐36 were significantly improved with liraglutide 3.0 mg vs. placebo. More patients on liraglutide 3.0 mg experienced meaningful improvement on the IWQOL‐Lite total (P < 0.0001) and the SF‐36 PCS (P < 0.0001) scores.nb_NO
dc.language.isoengnb_NO
dc.publisherWileynb_NO
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.subjectIWQOL-Litenb_NO
dc.subjectliraglutide 3.0 mgnb_NO
dc.subjectquality of lifenb_NO
dc.subjectSF-36v2nb_NO
dc.titleImprovements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight managementnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.rights.holder© 2016 The Authors.nb_NO
dc.subject.nsiVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Endokrinologi: 774nb_NO
dc.source.pagenumber233-242nb_NO
dc.source.volume6nb_NO
dc.source.journalClinical Obesitynb_NO
dc.source.issue4nb_NO
dc.identifier.doi10.1111/cob.12146
dc.identifier.cristin1357137
cristin.unitcode203,5,1,0
cristin.unitnameAvdeling for helsefag - Sogn og Fjordane
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal